Quick answerHypercalcemia of malignancy. Actions: infuse the prescribed 0.9% sodium chloride bolus; administer the prescribed IV zoledronic acid. Monitor: serum calcium corrected for albumin, and hourly urine output.
Why this is correctCalcium must be corrected for low albumin: 13.8 + 0.8 x (4.0 - 2.8) = about 14.8 mg/dL, a severe level. High calcium causes nephrogenic diabetes insipidus, so the client is volume depleted, which lowers renal calcium clearance and worsens the cycle. Isotonic saline breaks the cycle quickly, and a bisphosphonate stops osteoclast bone resorption, taking 2 to 4 days for full effect. The Endocrine Society guideline recommends an IV bisphosphonate or denosumab for hypercalcemia of malignancy.
Easy analogy or mental picturePicture a bathtub overflowing with calcium: saline pulls the drain open (renal excretion) while the bisphosphonate turns off the tap (bone resorption). You watch the water level (calcium) and the drain flow (urine output).
Memory hookStones, bones, groans, moans, and a short QT: fill the tank, then block the bone.
NCLEX decision ruleWhen an electrolyte emergency is driven by volume depletion, restore volume first; add drugs that act on the source next, and monitor the electrolyte and the output that clears it.
Why the other choices are wrongTumor lysis syndrome also occurs in cancer and can cause confusion and kidney injury, but it causes low calcium with high potassium, phosphorus, and uric acid; these are normal here, so rasburicase and a uric acid trend target the wrong problem. SIADH causes confusion but requires hyponatremia; sodium is 138 mEq/L, so fluid restriction would worsen dehydration and serum sodium is not the key trend. Brain metastasis is tempting in metastatic cancer, but the exam is nonfocal and calcium explains the findings, so pupil and motor checks are less specific. Furosemide before volume repletion is an outdated practice that worsens hypovolemia.
References
1Endocrine Society Clinical Practice Guideline: Treatment of Hypercalcemia of Malignancy in AdultsIV bisphosphonate or denosumab for hypercalcemia of malignancy, with initial IV hydration.